Cancer Management and Research (Jul 2024)
Importance of Testing for ROS1 Rearrangements in Non-Small Cell Lung Cancer in the Era of Targeted Therapy in a Latin American Country
Abstract
Alvaro Osorio,1,2 Liliana Fernandez-Trujillo,2,3 Juan G Restrepo,1,2 Luz F Sua,2,4 Catalina Proaño,5 Valeria Zuñiga-Restrepo2 1Department of Internal Medicine, Oncology Service, Fundación Valle Del Lili, Cali, Colombia; 2Faculty of Health Sciences, Universidad Icesi, Cali, Colombia; 3Department of Internal Medicine, Pulmonology Service, Fundación Valle Del Lili, Cali, Colombia; 4Department of Pathology and Laboratory Medicine, Fundación Valle Del Lili, Cali, Colombia; 5Clinical Research Center, Fundación Valle del Lili, Cali, ColombiaCorrespondence: Liliana Fernandez-Trujillo, Department of Internal Medicine, Pulmonology Service, Interventional Pulmonology, Avenida Simón Bolívar. Cra. 98 No. 18-49, Fundación Valle del Lili, Tower 6, 4th Floor, Cali, 760032, Colombia, Tel +57 3155006300, Email [email protected]; [email protected]: Lung cancer is the leading cause of cancer-related deaths worldwide. However, with the optimization of screening strategies and advances in treatment, mortality has been decreasing in recent years. In this study, we describe non-small cell lung cancer patients diagnosed between 2021 and 2022 at a high-complexity hospital in Latin America, as well as the immunohistochemistry techniques used to screen for ROS1 rearrangements, in the context of the recent approval of crizotinib for the treatment of ROS1 rearrangements in non-small cell lung cancer in Colombia.Methods: A descriptive cross-sectional study was conducted. Sociodemographic, clinical, and molecular pathology information from non-small cell lung cancer individuals who underwent immunohistochemistry to detect ROS1 rearrangements between 2021 and 2022 at Fundación Valle del Lili (Cali, Colombia) was recorded. The clinical outcomes of confirmed ROS1 rearrangements in non-small cell lung cancer patients were reported.Results: One hundred and thirty-six patients with non-small cell lung cancer were included. The median age at diagnosis was 69.8 years (interquartile range 61.9– 77.7). At diagnosis, 69.8% (n = 95) were at stage IV. ROS1 immunohistochemistry was performed using the monoclonal D4D6 antibody clone in 54.4% (n = 74) of the cases, while 45.6% (n = 62) were done with the monoclonal SP384 antibody clone. Two patients were confirmed to have ROS1 rearrangements in non-small cell lung cancer using next-generation sequencing and received crizotinib. On follow-up at months 5.3 and 7.0, one patient had a partial response, and the other had oligo-progression, respectively.Conclusion: Screening for ROS1 rearrangements in non-small cell lung cancer is imperative, as multiple prospective studies have shown improved clinical outcomes with tyrosine kinase inhibitors. Given the recent approval of crizotinib in Colombia, public health policies must be oriented toward early detection of driver mutations and prompt treatment. Additionally, future approvals of newly tested tyrosine kinase inhibitors should be anticipated.Keywords: non-small cell lung cancer, ROS1, proto-oncogene receptor tyrosine kinase, immunohistochemistry, next generation sequencing, tyrosine kinase inhibitor
